Researchers have identified a promising blood-based biomarker that could help detect the earliest biological warning signs of ovarian cancer, potentially years before an invasive tumour becomes visible. The discovery, led by scientists at Hoag Family Cancer Institute in California, focuses on an RNA molecule called Tu-Stroma, which appears in the bloodstream when certain precancerous changes develop in the fallopian tubes.
Published in Nature Medicine on November 10, 2026, the study found that the experimental blood test detected 92.3% of women with a precancerous condition associated with high-grade serous ovarian cancer and correctly identified 98.2% of healthy women in a validation group. Although the findings represent a promising development in early cancer detection, researchers say further clinical studies are needed before the test can become part of routine medical care.
Scientists Identify a Molecular Warning Signal in Blood
The research was led by Dr. Rajan Gogna and Dr. Esha Madan of Hoag Family Cancer Institute in Newport Beach, California.
Instead of focusing on detecting small ovarian tumours, the researchers investigated whether changes occurring before invasive cancer develops could be identified through a blood test.
Their attention turned to an RNA molecule called Tu-Stroma, a long non-coding RNA associated with interactions between developing tumour cells and surrounding healthy tissue.
The researchers found that Tu-Stroma was present at elevated levels in blood samples from women with serous tubal intraepithelial carcinoma, commonly known as STIC.
STIC is a microscopic, non-invasive precancerous lesion that develops in the lining of the fallopian tubes. It is considered an important precursor to high-grade serous carcinoma, the most common and deadly form of epithelial ovarian cancer.
Because these lesions are extremely small, they are difficult to identify using conventional imaging techniques or standard cancer blood tests.
The discovery suggests that a molecular signal released into the bloodstream could provide information about these early cellular changes before an invasive tumour develops.
How the Experimental Blood Test Works
The test measures Tu-Stroma contained in extracellular vesicles circulating in the blood.
Extracellular vesicles are tiny membrane-bound particles released by cells. They carry biological material, including RNA and proteins, between different cells and tissues.
Researchers found that Tu-Stroma associated with developing cancer can be detected in these circulating particles.
The team collected and analysed blood samples from 506 individuals, including women with normal reproductive tissue, benign ovarian or adnexal conditions, STIC and high-grade serous carcinoma at different stages.
The researchers then evaluated whether Tu-Stroma levels could distinguish women with precancerous or cancerous conditions from those without them.
The results showed that the biomarker could identify disease-related molecular changes with high accuracy in the studied groups.
Test Detects 92.3% of Precancerous Cases
One of the most important findings came from a separate validation group.
The experimental test detected STIC in 92.3% of affected women and correctly identified 98.2% of healthy women.
These figures represent sensitivity and specificity, two important measurements used to evaluate diagnostic tests.
| Measurement | Reported performance |
|---|---|
| Detection of women with STIC | 92.3% |
| Correct identification of healthy women | 98.2% |
| Main biomarker | Tu-Stroma RNA |
| Biological material measured | Serum extracellular vesicles |
| Study population | 506 individuals |
| Research publication | Nature Medicine |
| Publication date | November 10, 2026 |
The researchers also compared Tu-Stroma with CA125, a protein commonly used in ovarian cancer assessment.
For detecting STIC compared with healthy controls, Tu-Stroma achieved an area under the receiver operating characteristic curve (AUC) of 0.99, compared with 0.59 for CA125.
An AUC closer to 1 indicates stronger discrimination between the groups being evaluated.
The results suggest that Tu-Stroma could provide information about precancerous changes that conventional blood markers may miss.
However, these results come from a research study involving selected participants. They do not establish how the test would perform in a general population undergoing routine screening.
Why Early Detection of Ovarian Cancer Is Difficult
Ovarian cancer is often diagnosed at an advanced stage because its early symptoms can be vague or mistaken for common digestive and abdominal problems.
Some women experience persistent bloating, pelvic discomfort, abdominal swelling, changes in appetite or feeling full quickly. These symptoms are not specific to ovarian cancer, which makes early identification challenging.
High-grade serous ovarian cancer is particularly difficult to detect because it can originate from microscopic changes in the fallopian tubes rather than developing directly inside the ovaries.
The precursor lesion, STIC, is generally identified through examination of fallopian tube tissue removed during surgery.
This creates a major challenge for women with inherited genetic risk factors, including pathogenic BRCA1 or BRCA2 variants. Some may consider preventive surgery to reduce their future cancer risk, even when there is no direct evidence that precancerous lesions are already present.
A reliable blood-based marker could eventually provide additional biological information to help doctors assess these situations.
Could the Blood Test Help Women With Genetic Risk Factors?
The findings may be particularly important for women with an elevated inherited risk of ovarian cancer.
People carrying certain genetic variants, including BRCA1 and BRCA2 mutations, have a higher lifetime risk of developing ovarian and fallopian tube cancers.
Preventive surgery to remove the fallopian tubes and ovaries can substantially reduce this risk, but it is a major decision with permanent consequences.
The study’s researchers believe that detecting molecular warning signals could eventually help doctors make more informed decisions about monitoring and prevention.
In a modelled high-risk population, approximately 72% of positive results were predicted to be accurate, while negative results were expected to be correct nearly 100% of the time.
These figures are model-based estimates rather than results from a large prospective screening programme. Their real-world performance will need to be established through additional clinical research.
How Tu-Stroma Compares With Traditional CA125 Testing
CA125 is one of the best-known blood markers used in ovarian cancer assessment.
However, it has important limitations. CA125 levels can increase because of several non-cancerous conditions, including endometriosis, menstruation and pelvic inflammation.
Some women with ovarian cancer may also have CA125 levels that are not significantly elevated, particularly during earlier stages.
The researchers found that Tu-Stroma performed better than CA125 in distinguishing STIC from healthy controls and women with benign adnexal conditions in their study.
| Comparison | Tu-Stroma | CA125 |
|---|---|---|
| STIC versus healthy controls (AUC) | 0.99 | 0.59 |
| STIC versus benign adnexal masses (AUC) | 0.99 | 0.31 |
| High-grade serous carcinoma versus healthy controls (AUC) | 0.99 | 0.96 |
| High-grade serous carcinoma versus benign masses (AUC) | 0.98 | 0.84 |
These comparisons indicate that Tu-Stroma could be a valuable additional biomarker, particularly for identifying precursor lesions.
However, outperforming CA125 in a research dataset does not automatically establish that Tu-Stroma is suitable for population-wide screening or that it should replace existing clinical assessments.
Researchers Plan Further Clinical Studies
Despite the promising results, the experimental test is not yet available as a routine diagnostic service.
The research analysed previously collected blood samples from individuals with established diagnoses. This is different from prospectively testing people who have not yet been diagnosed and following them over time.
The researchers at Hoag plan to conduct additional prospective studies involving women with and without inherited ovarian cancer risk factors.
These studies will investigate:
- How early Tu-Stroma becomes detectable before invasive cancer develops.
- Whether the biomarker can reliably identify women with STIC in real-world clinical settings.
- How accurately the test performs across larger and more diverse populations.
- Whether its results can improve decisions about monitoring and preventive surgery.
- Whether using the test can ultimately improve patient outcomes.
The researchers also need to determine how often false-positive results occur in routine clinical populations and whether the test provides meaningful benefits beyond existing medical assessments.
The Bigger Picture
The discovery represents a different approach to cancer detection. Rather than waiting for a tumour to become large enough to identify through imaging or conventional testing, researchers are investigating molecular signals that appear during the earliest stages of disease development.
The Tu-Stroma findings also highlight the importance of studying the biological processes surrounding cancer cells. The marker is associated with interactions between developing tumour tissue and neighbouring healthy cells, offering researchers a potential way to identify changes before invasive disease becomes established.
If future studies confirm its accuracy, the technology could help improve ovarian cancer surveillance and provide additional information for women at elevated genetic risk. However, translating a promising biomarker into an effective screening programme will require substantial clinical validation.
Looking Ahead
The next stage of research will focus on prospective clinical studies involving larger groups of women, including those with inherited cancer risk factors. Scientists will need to establish whether Tu-Stroma can identify precancerous changes before symptoms appear and whether test results can reliably guide medical decisions. Until then, the findings should be considered an important research development rather than an available screening breakthrough.
For ovarian cancer research, the study offers a promising new direction by suggesting that microscopic precancerous changes can leave detectable molecular signals in the bloodstream. If validated in future trials, Tu-Stroma could eventually help doctors identify women who need closer investigation and make more informed decisions about prevention. The ultimate goal is to detect disease earlier, when intervention may have a greater chance of improving outcomes.
SEO Title: New Blood Test Detects Early Ovarian Cancer Warning Signs With 92% Accuracy
Meta Description: A Nature Medicine study found that the Tu-Stroma blood biomarker detected 92.3% of ovarian cancer precursor cases, offering hope for earlier detection.
URL Slug: blood-test-detects-early-ovarian-cancer-warning-signs
Focus Keyphrase: blood test for early ovarian cancer detection
Secondary Keywords: Tu-Stroma blood test, ovarian cancer research, early cancer detection, STIC precancerous lesion, Hoag Family Cancer Institute, CA125 test, ovarian cancer biomarkers
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
